Pfizer and BioNTech plan to seek approval from US and EU regulators for using the third dose of the coronavirus vaccine. An additional dose of the vaccine will help maintain the required level of protection against coronavirus even six months after full vaccination.
Studies have shown that the third dose of the vaccine elicits an immune response with antibody titers that are 5 to 10 times higher than after two vaccinations. This was reported by the BioNTech press service.
The companies plan to publish more accurate data and appeal with them to the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and other regulatory bodies.
In addition, the companies are developing an updated vaccine version that will be effective against the Delta strain. BioNTech is ready to start clinical trials in August if it gets approval from the regulator.
The company analyzed data from patients from the United States and came to the conclusion that the Pfizer/BioNTech vaccine efficacy drops to almost 80% in six months. However, the vaccine is still 94% effective against the severe course of the coronavirus.
Recall that Ukrainians are vaccinated with the following drugs:
- British-Swedish AstraZeneca;
- Chinese Sinovac (CoronaVac);
- American-German Pfizer (BioNTech).
